1039 ET - Gilead Sciences are weaker following news the Health and Human Services Department is considering cutting funding for HIV prevention, but analysts believe that threat poses only moderate risk. Potential cuts to CDC funding would not limit access to pre-exposure prophylaxis, a preventative treatment for HIV patients, because the organization only works on research, not providing the drugs, JPMorgan analysts say. The Centers for Disease Control and Prevention, which is part of HHS, spent about $1.3 billion in HIV funding as of 2023, BMO analyst Evan David Seigerman says, the removal of which "should only represent a modest headwind" to Gilead. Gilead is off 3.7%. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
March 19, 2025 10:39 ET (14:39 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。